Drugs / FT-1101
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02543879 | Sep 2015 → Mar 2019 | acute myeloid leukemia, myelodysplastic syndrome, non-Hodgkin lymphoma | Forma Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FT-1101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02543879 ↗ |
| Action | Inhibit | “Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies” NCT02543879 ↗ |
| Route | Oral | “administered FT-1101 at 10 mg, oral capsules” NCT02543879 ↗ |